Buy Nurix (NRIX): Bexobrutideg Pivotal Runway and Multiple Near-Term Catalysts

Hook and thesis

Nurix Therapeutics (NRIX) is a buy here. The stock is trading at $16.24 after a solid corporate update and continued clinical momentum for bexobrutideg (NX-5948), a BTK degrader with an 83% objective response rate in Phase 1 and a median progression-free survival of 22.1 months reported at ASH. Management is running a registrational program - DAYBreak - with Phase 2 enrollment ongoing for accelerated approval in relapsed/refractory CLL and plans to start a Phase 3 confirmatory study by mid-2026. Those program milestones, combined with a $540.7 million cash balance and a recent $250 million registered offering, create a clear path to de-risk value over the next 6-12 months.

Our Strong Buy stance is tactical and time-bound. We view NRIX as a high-upside, event-driven biotech trade: clinical readouts and trial starts should re-rate the story if efficacy and safety remain consistent with Phase 1 data. At the same time, the company’s market capitalization of roughly $1.67 billion looks reasonable when you factor in cash on hand and the potential for bexobrutideg to be a registration-ready asset in a large addressable market.

Why the market should care - business summary and fundamental driver

Nurix is a clinical-stage biopharma focused on small molecules and antibody therapies that modulate cellular protein levels to treat cancer and inflammatory diseases. Its lead program, bexobrutideg (a BTK degrader), has two features that matter to investors: demonstrated activity in treatment-resistant chronic lymphocytic leukemia (CLL) and a path toward regulatory registration.

Key fundamentals that drive our interest:

• Bexobrutideg Phase 1 results presented at ASH showed an 83% objective response rate and median PFS of 22.1 months - efficacy metrics that compare favorably to many BTK inhibitors in resistant disease.
• DAYBreak pivotal Phase 2 enrollment is ongoing for accelerated approval in relapsed/refractory CLL, with a Phase 3 DAYBreak CLL-306 planned to begin by mid-2026 (corporate update 04/08/2026).
• Balance sheet: Nurix reported a cash position of $540.7 million in its Q1 2026 update, providing runway to hit upcoming milestones without urgent dilution.
• Institutional conviction: Redmile Group increased its stake in the company in 2026, which signals conviction from an active healthcare investor base.

What the numbers say

Several points matter from the table above. First, the company is pre-profit and spending heavily on development: free cash flow is deeply negative and the company recorded an $87.2 million loss in Q1 2026. That said, the cash balance of $540.7M provides more than a near-term runway to execute the registrational program. Second, the valuation multiples look rich on a revenue basis - price-to-sales of ~19x - but biotech valuations are driven by binary clinical outcomes, not trailing revenue. The key valuation anchor is the probability-weighted value of bexobrutideg reaching market and the timeline to that event.

Technical and market structure context

NRIX’s technicals are constructive for buyers: the stock is above the 10-, 20-, and 50-day SMAs ($15.54, $15.29, $15.78 respectively); RSI is neutral at 55.8, and the MACD shows bullish momentum. Short interest has ticked up in recent reporting periods (short interest ~16.18M with days-to-cover ~19.6 on 03/13/2026), indicating both potential squeeze dynamics around positive catalysts and a concentration of skeptics to absorb good news.

Catalysts (what will move the stock)

• DAYBreak Phase 2 enrollment updates and topline data - continued enrollment progress and early efficacy/safety signals should lift the multiple.
• Initiation of Phase 3 DAYBreak CLL-306 by mid-2026 - the official start of a confirmatory trial is a derisking step for the registration path.
• Additional ASH-style scientific disclosures or updated survival/outcomes data that confirm durability beyond the Phase 1 readouts (83% ORR, median PFS 22.1 months).
• Expansion into immunology/inflammation with a tablet formulation aiming at an IND submission in 2026 - a positive IND could broaden the pipeline’s optionality.
• Balance sheet events - further non-dilutive collaborations or licensing deals would materially de-risk runway and upside.

Trade plan - entry, stops, targets, and horizon

We favor an event-driven long with the following parameters:

• Entry price: $16.20
• Stop loss: $12.75
• Target price: $24.00
• Horizon: long term (180 trading days) - expect the position to play through pivotal enrollment progress, the planned Phase 3 start, and possibly interim signals from registrational efforts.

Rationale: entry near $16 locks in a favorable risk/reward vs. the $12.75 stop while leaving upside toward the 52-week high and beyond if the Phase 2 to Phase 3 handoff and interim efficacy signals stay favorable. The 180 trading day horizon is designed to capture the material derisking events that should occur over the next 6-9 months.

Risks and counterarguments

Biotech investing is binary and Nurix is no exception. Below are the primary risks, plus a counterargument that tempers one of those risks.

• Clinical risk - Phase 2/3 results may fail to replicate Phase 1 efficacy or reveal safety/tolerability issues that impede approval. A negative or ambiguous readout would likely cause a large downside move.
• Execution risk - trial enrollment delays or regulatory setbacks (e.g., trial design or endpoint changes) could push timelines and increase cash burn.
• Financial risk - free cash flow is negative and the company lost $87.2M in Q1 2026. While cash of $540.7M provides runway, large studies or unexpected costs could force further capital raises and dilute shareholders.
• Competition and market dynamics - BTK inhibitors and degraders are a crowded space; competitors could produce incremental efficacy or safety data that reduces the commercial potential of bexobrutideg.
• Short interest and volatility - elevated short interest and event-driven positioning can create sharp intra-period swings, increasing execution risk for traders.

Counterargument - The Phase 1 dataset is relatively mature: an 83% ORR and median PFS of 22.1 months are meaningful in relapsed/refractory CLL. That level of activity, coupled with a clear registrational plan and solid cash runway, reduces the probability that the program will fail solely due to underpowered or poorly designed trials. In short, the quality of the Phase 1 signal plus existing cash gives the company a real shot at a positive registrational outcome - which is why we are constructive.

What would change our view

We would dial back our conviction if any of the following occur:

• Trial data show materially lower response rates or unacceptable safety signals in the pivotal setting.
• Management discloses a near-term cash runway that is insufficient to reach key readouts without substantial dilution.
• Competitive data from other BTK platforms demonstrate clear superiority in the same patient population, compressing addressable market assumptions.

Conclusion

Nurix offers an asymmetric risk-reward at current levels. The company is trading at $16.24 with a market cap near $1.67B, a robust cash balance of $540.7M, and a registrational program for a BTK degrader that produced an 83% ORR in Phase 1. Those facts underpin our Strong Buy call and the trade plan above. This is a high-risk, high-reward biotech trade that belongs in the speculative portion of a portfolio but is actionable given upcoming catalysts and the company’s cash runway.

If the company can keep the DAYBreak program on track, start Phase 3 by mid-2026, and replicate Phase 1 durability in registrational settings, the shares should re-rate meaningfully. We’ll reassess if trial efficacy slips, cash runway shrinks materially, or the competitive landscape shifts sharply.